CY1111912T1 - Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων - Google Patents

Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων

Info

Publication number
CY1111912T1
CY1111912T1 CY20111100954T CY111100954T CY1111912T1 CY 1111912 T1 CY1111912 T1 CY 1111912T1 CY 20111100954 T CY20111100954 T CY 20111100954T CY 111100954 T CY111100954 T CY 111100954T CY 1111912 T1 CY1111912 T1 CY 1111912T1
Authority
CY
Cyprus
Prior art keywords
osteoklasts
restricting
activity
receptors
isolated
Prior art date
Application number
CY20111100954T
Other languages
Greek (el)
English (en)
Inventor
Dirk M Anderson
Laurent J Galibert
Original Assignee
Immunex Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corporation filed Critical Immunex Corporation
Publication of CY1111912T1 publication Critical patent/CY1111912T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CY20111100954T 1998-05-14 2011-10-06 Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων CY1111912T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8548798P 1998-05-14 1998-05-14
US11083698P 1998-12-03 1998-12-03
EP08015570A EP2009025B1 (en) 1998-05-14 1999-05-13 Method of inhibiting osteoclast activity

Publications (1)

Publication Number Publication Date
CY1111912T1 true CY1111912T1 (el) 2015-11-04

Family

ID=26772773

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100954T CY1111912T1 (el) 1998-05-14 2011-10-06 Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων

Country Status (12)

Country Link
US (2) US20050089522A1 (enExample)
EP (2) EP1076699B1 (enExample)
JP (1) JP2002514418A (enExample)
AT (2) ATE517916T1 (enExample)
AU (1) AU762574B2 (enExample)
CA (1) CA2328140C (enExample)
CY (1) CY1111912T1 (enExample)
DE (1) DE69939822D1 (enExample)
DK (1) DK2009025T3 (enExample)
ES (1) ES2317694T3 (enExample)
PT (1) PT2009025E (enExample)
WO (1) WO1999058674A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
JP3523650B2 (ja) 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU7705098A (en) * 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6891082B2 (en) 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
CA2647796A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Method of inhibiting osteoclast activity
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2002064782A2 (en) * 2001-02-09 2002-08-22 Maxygen Holdings Ltd. Rank ligand-binding polypeptides
CA2441538A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
EP1385872A4 (en) * 2001-05-11 2004-12-15 Res Dev Foundation NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS
DE02726901T1 (de) * 2001-05-17 2004-07-15 Immunex Corp., Seattle Therapeutische verwendung von rang-antagonisten
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
WO2003065972A2 (en) * 2001-10-12 2003-08-14 Barnes-Jewish Hospital Methods for screening osteogenic compounds
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
AU2003242265A1 (en) * 2002-06-07 2003-12-22 Sankyo Company, Limited Combined effects of therapeutic or preventive agent composition for bone breakage
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
WO2008150025A1 (ja) * 2007-06-05 2008-12-11 Oriental Yeast Co., Ltd. 新しい骨量増加薬
JP6403999B2 (ja) * 2014-06-05 2018-10-10 株式会社細川洋行 レトルト包装用積層体及び容器

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150090A (en) * 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
PT672141E (pt) * 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5741667A (en) 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
NZ311335A (en) * 1995-06-07 1998-05-27 Immunex Corp Cd40l muteins and their use as ligands
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
JPH1057071A (ja) 1996-08-19 1998-03-03 Snow Brand Milk Prod Co Ltd 新規ｄｎａ及びそれを用いた蛋白質の製造方法
PT1114864E (pt) 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
WO1998028423A2 (en) 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Compositions and methods of use for osteoclast inhibitory factors
WO1999058674A2 (en) 1998-05-14 1999-11-18 Immunex Corporation Method of inhibiting osteoclast activity
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
JP3523650B2 (ja) * 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
AU7469998A (en) 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
AU7705098A (en) 1997-05-29 1998-12-30 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6087555A (en) 1997-10-15 2000-07-11 Amgen Inc. Mice lacking expression of osteoprotegerin
WO1999029865A2 (en) 1997-12-12 1999-06-17 The Rockefeller University A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
JPH11266872A (ja) 1998-03-20 1999-10-05 Suntory Ltd ＮＦ−κＢの活性化を抑制する物質のスクリーニング方法
US6790823B1 (en) 1998-04-23 2004-09-14 Amgen Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
HUP0102492A2 (hu) 1998-06-19 2001-11-28 Smithkline Beecham Corp. Amino-indanon származékok alkalmazása NF-kB transzkripciós faktor inhibitor hatású gyógyszerkészítmények előállítására
HUP0102782A3 (en) 1998-06-19 2002-12-28 Smithkline Beecham Corp Salycilanilide as inhibitors of transcription factor nf-kb
AU6078500A (en) 1999-07-09 2001-01-30 Amgen, Inc. Combination therapy for conditions leading to bone loss
US20030144187A1 (en) 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
KR20010085996A (ko) 1999-09-03 2001-09-07 스티븐 엠. 오드레 암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
AUPQ314799A0 (en) 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
WO2001062932A1 (en) 2000-02-23 2001-08-30 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU2001288342A1 (en) 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors

Also Published As

Publication number Publication date
EP2009025B1 (en) 2011-07-27
ATE517916T1 (de) 2011-08-15
ATE412746T1 (de) 2008-11-15
EP1076699B1 (en) 2008-10-29
CA2328140A1 (en) 1999-11-18
DK2009025T3 (da) 2011-11-14
DE69939822D1 (de) 2008-12-11
WO1999058674A2 (en) 1999-11-18
ES2317694T3 (es) 2009-04-16
US20050089522A1 (en) 2005-04-28
EP1076699A2 (en) 2001-02-21
EP2009025A1 (en) 2008-12-31
US7790684B2 (en) 2010-09-07
AU3988899A (en) 1999-11-29
CA2328140C (en) 2012-03-13
JP2002514418A (ja) 2002-05-21
AU762574B2 (en) 2003-06-26
WO1999058674A3 (en) 2000-02-10
PT2009025E (pt) 2011-09-19
US20090004196A1 (en) 2009-01-01

Similar Documents

Publication Publication Date Title
PT2009025E (pt) Método de inibição da actividade dos osteoclastos
DK0751789T3 (da) Gel til behandling af hudsygdomme og til desinfektion af huden
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ID29393A (id) Komposisi pengobatan kanker dan metoda penggunaan minyak-minyak esensil tanaman alamiah
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
DE69814394D1 (de) Verwendung von levobupivacain
BRPI0414215A (pt) tienopirazóis
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
ATE82127T1 (de) N-acetylglucosamin-zubereitungen zur buccalen anwendung.
BG105275A (en) Tan-1057 derivatives
DK1063981T3 (da) Anvendelse af selegilin eller desmethylselegilin til behandling af sår, brandsår og dermatologiske skader
DE60108094D1 (de) Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
EP1436308A4 (en) ANTISENSE MODULATION OF IL-1 RECEPTOR ASSOCIATED KINASE-4 EXPRESSION
TR200200278T2 (tr) Kalsilitik bileşimler
BR0010560A (pt) 3-piridil-4-arilpirrois substituìdos e métodos terapêuticos e profiláticos relacionados
ATE159171T1 (de) Arzneimittelzusammensetzung enthaltend tcf-ii
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
HUP9900007A2 (hu) Készítmény baromfialom kezelésére
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
BR0016168A (pt) Combinações terapêuticas de (s)-2-(benzilaminometil)-2,3,8,9tetrahidro-7h-1,4-dioxi no[2,3 -e]indol-8-ona e neurolépticos para o tratamento ou prevenção de distúrbios psicóticos
DE50000562D1 (de) Mittel zur behandlung von pigmentierungsstörungen